JPWO2021155467A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021155467A5 JPWO2021155467A5 JP2022548039A JP2022548039A JPWO2021155467A5 JP WO2021155467 A5 JPWO2021155467 A5 JP WO2021155467A5 JP 2022548039 A JP2022548039 A JP 2022548039A JP 2022548039 A JP2022548039 A JP 2022548039A JP WO2021155467 A5 JPWO2021155467 A5 JP WO2021155467A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- hydrogen
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025279101A JP2026053548A (ja) | 2020-02-04 | 2025-12-23 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969894P | 2020-02-04 | 2020-02-04 | |
| US62/969,894 | 2020-02-04 | ||
| PCT/CA2021/050122 WO2021155467A1 (en) | 2020-02-04 | 2021-02-04 | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025279101A Division JP2026053548A (ja) | 2020-02-04 | 2025-12-23 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023512821A JP2023512821A (ja) | 2023-03-29 |
| JP2023512821A5 JP2023512821A5 (https=) | 2024-02-13 |
| JPWO2021155467A5 true JPWO2021155467A5 (https=) | 2024-02-13 |
| JP7824222B2 JP7824222B2 (ja) | 2026-03-04 |
Family
ID=77199114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548039A Active JP7824222B2 (ja) | 2020-02-04 | 2021-02-04 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 |
| JP2025279101A Pending JP2026053548A (ja) | 2020-02-04 | 2025-12-23 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025279101A Pending JP2026053548A (ja) | 2020-02-04 | 2025-12-23 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11453689B2 (https=) |
| EP (1) | EP4100403A4 (https=) |
| JP (2) | JP7824222B2 (https=) |
| KR (1) | KR20220137085A (https=) |
| CN (1) | CN115380028A (https=) |
| AU (1) | AU2021215709A1 (https=) |
| BR (1) | BR112022015379A2 (https=) |
| CA (1) | CA3166940A1 (https=) |
| IL (1) | IL295374A (https=) |
| MX (1) | MX2022009528A (https=) |
| WO (1) | WO2021155467A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022009528A (es) * | 2020-02-04 | 2022-11-14 | Mindset Pharma Inc | Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| AU2022229037A1 (en) * | 2021-03-02 | 2023-09-28 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| JP2024520017A (ja) * | 2021-05-26 | 2024-05-21 | マインドセット ファーマ インコーポレイテッド | 幻覚剤と脂肪酸との併用 |
| EP4347559A4 (en) * | 2021-06-02 | 2025-04-09 | Saint Joseph's University | FLUORINATED TRYPTAMINE COMPOUNDS, RELATED ANALOGUES AND METHODS USING THEM |
| CA3229361A1 (en) * | 2021-08-20 | 2023-02-23 | Abdelmalik Slassi | 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto |
| EP4452939A4 (en) * | 2021-12-24 | 2025-12-10 | Kuleon Llc | SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS |
| AU2023215456A1 (en) * | 2022-02-01 | 2024-08-01 | Caamtech, Inc. | Psychedelic compounds and their therapeutic uses |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| KR20250034020A (ko) * | 2022-04-19 | 2025-03-10 | 마인드셋 파마 인크. | 세로토닌 관련 장애를 치료하는 데 유용한 세로토닌성 제제로서의 인돌린 유도체 |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| WO2025104491A1 (en) | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545644A (en) | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
| US5559129A (en) | 1990-10-15 | 1996-09-24 | Pfizer Inc | Indole derivatives |
| US5607951A (en) | 1990-10-15 | 1997-03-04 | Pfizer Inc | Indole derivatives |
| US5120749A (en) | 1991-02-20 | 1992-06-09 | Abbott Laboratories | Platelet activating antagonists |
| TW288010B (https=) * | 1992-03-05 | 1996-10-11 | Pfizer | |
| SK280193B6 (sk) * | 1992-04-07 | 1999-09-10 | Pfizer Inc. | Indolové deriváty predstavujúce 5-ht1 agonisty, fa |
| ATE144773T1 (de) * | 1993-04-22 | 1996-11-15 | Pfizer Res & Dev | Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne |
| AP486A (en) * | 1993-04-27 | 1996-04-16 | Pfizer | Indole derivatives. |
| FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| US5955462A (en) | 1996-10-31 | 1999-09-21 | Harbor Branch Oceanographic Institution, Inc. | Anti-neurogenic inflammatory compounds and compositions and methods of use thereof |
| US6100291A (en) | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| GB9816263D0 (en) | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
| US6218423B1 (en) | 1998-08-14 | 2001-04-17 | Gpi Nil Holdings, Inc. | Pyrrolidine derivatives for vision and memory disorders |
| GB9923314D0 (en) | 1999-10-01 | 1999-12-08 | Pfizer Ltd | Acylation process |
| WO2001094310A1 (en) | 2000-06-07 | 2001-12-13 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Methods for making bis-heterocyclic alkaloids |
| US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
| WO2004106298A1 (en) | 2003-05-30 | 2004-12-09 | Janssen Pharmaceutica N.V. | Indole derivatives with an improved antipsychotic activity |
| US7700612B2 (en) * | 2003-12-23 | 2010-04-20 | Abraxis Bioscience, Llc | Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications |
| ATE474833T1 (de) | 2004-09-22 | 2010-08-15 | Janssen Pharmaceutica Nv | Inhibitoren der wechselwirkung zwischen mdm2 und p53 |
| ES2357129T3 (es) | 2005-04-13 | 2011-04-19 | Neuraxon Inc. | Compuestos indólicos sustituidos que tienen actividad inhibidora de nos. |
| US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
| JP5137849B2 (ja) | 2006-01-19 | 2013-02-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体 |
| US20090306137A1 (en) * | 2006-05-22 | 2009-12-10 | Wolfgang Curt D | Treatment for depressive disorders |
| US7964728B2 (en) | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
| WO2008036967A2 (en) | 2006-09-22 | 2008-03-27 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds as lasy activators |
| US20090014868A1 (en) | 2007-07-10 | 2009-01-15 | International Business Machines Corporation | Manufacturing ic chip in portions for later combining, and related structure |
| KR20100103799A (ko) | 2007-11-16 | 2010-09-28 | 네우렉슨 인코포레이티드 | 내장통을 치료하기 위한 인돌 화합물 및 방법 |
| US20100022581A1 (en) | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| WO2010132072A1 (en) | 2009-05-15 | 2010-11-18 | Neuraxon, Inc | Treatment or prevention of migraine by dosing at aura |
| JP5959537B2 (ja) | 2011-01-28 | 2016-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ピリジニル−ピリミジン及び医薬としてのその使用 |
| PT3160464T (pt) * | 2014-06-26 | 2018-10-12 | Contera Pharma Aps | 6-hidroxibuspirona para uso no tratamento de transtornos do movimento |
| GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| MA42769B1 (fr) * | 2015-09-10 | 2019-12-31 | Suven Life Sciences Ltd | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
| WO2018064465A1 (en) | 2016-09-29 | 2018-04-05 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| US20190358238A1 (en) | 2016-11-16 | 2019-11-28 | University Of South Florida | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES |
| CA3077053A1 (en) * | 2017-09-27 | 2019-04-04 | Ohio State Innovation Foundation | Methods and compositions for inhibition of stat3 |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12090145B2 (en) | 2018-08-20 | 2024-09-17 | Yale University | Combination therapy for treating or preventing depression or other mood diseases |
| AU2020215150B8 (en) | 2019-01-30 | 2025-07-03 | Diamond Therapeutics Inc. | Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders |
| EP4219498A1 (en) | 2019-03-07 | 2023-08-02 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| CA3160793A1 (en) | 2019-12-04 | 2021-06-10 | Neonmind Biosciences Inc. | Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder |
| MX2022009528A (es) * | 2020-02-04 | 2022-11-14 | Mindset Pharma Inc | Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. |
| JP2023514559A (ja) | 2020-02-05 | 2023-04-06 | イエール ユニバーシティ | 頭痛障害の幻覚剤処置 |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| CN115867533B (zh) | 2020-06-30 | 2024-07-23 | 加拿大瑞安神经科学公司 | 色胺前药 |
| WO2022018709A1 (en) | 2020-07-21 | 2022-01-27 | Ai Pharmaceuticals Jamaica Limited | Compositions and methods for treatment of psychoses and psychotic disorders |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2021
- 2021-02-04 MX MX2022009528A patent/MX2022009528A/es unknown
- 2021-02-04 EP EP21751045.2A patent/EP4100403A4/en active Pending
- 2021-02-04 KR KR1020227030622A patent/KR20220137085A/ko active Pending
- 2021-02-04 AU AU2021215709A patent/AU2021215709A1/en active Pending
- 2021-02-04 JP JP2022548039A patent/JP7824222B2/ja active Active
- 2021-02-04 IL IL295374A patent/IL295374A/en unknown
- 2021-02-04 CN CN202180026721.8A patent/CN115380028A/zh active Pending
- 2021-02-04 CA CA3166940A patent/CA3166940A1/en active Pending
- 2021-02-04 WO PCT/CA2021/050122 patent/WO2021155467A1/en not_active Ceased
- 2021-02-04 BR BR112022015379A patent/BR112022015379A2/pt unknown
- 2021-07-28 US US17/387,864 patent/US11453689B2/en active Active
-
2022
- 2022-08-02 US US17/879,320 patent/US12054504B2/en active Active
-
2024
- 2024-06-19 US US18/747,540 patent/US20240336641A1/en active Pending
-
2025
- 2025-12-23 JP JP2025279101A patent/JP2026053548A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021155470A5 (https=) | ||
| JPWO2021155468A5 (https=) | ||
| IL295371A (en) | Psilocyin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders | |
| JPWO2021155467A5 (https=) | ||
| Reddy et al. | Library design, synthesis, and screening: pyridine dicarbonitriles as potential prion disease therapeutics | |
| Jacobs et al. | Boron-pleuromutilins as anti-Wolbachia agents with potential for treatment of onchocerciasis and lymphatic filariasis | |
| JP2009538910A5 (https=) | ||
| JP6673939B2 (ja) | Ｇｐｒ５２に関連する障害の治療または予防に有用なｇｐｒ５２のモジュレーターとしての１−ヘテロアリール−インドリン−４−カルボキサミド | |
| RU93058600A (ru) | Производные пиперидина, обладающие анксиолитическим действием, фармацевтическая композиция на их основе | |
| JP6421185B2 (ja) | ベンゾイミダゾール−プロリン誘導体の使用 | |
| CY1114702T1 (el) | Νεοι εναnτιομερως καθαροι βητα αγωνιστες, μεθοδος για την παραγωγη τους και χρηση αυτων ως φαρμακων | |
| JP2006521345A (ja) | ニコチン性アセチルコリン受容体の正のアロステリック調節剤 | |
| AU2021262281B2 (en) | 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof | |
| JP2019511546A (ja) | 新規なｎ−［（ピリミジニルアミノ）プロパニル］−およびｎ−［（ピリジニルアミノ）プロパニル］アリールカルボキサミド | |
| JP2025502712A (ja) | シクロプロピル化合物 | |
| JP2023512762A (ja) | ムスカリン性受容体４アンタゴニストおよび使用方法 | |
| JP3521214B2 (ja) | ４，５−ジヒドロイソオキサゾリルアルキルピペラジン誘導体とその製造方法並びにドーパミン拮抗剤 | |
| JP2024542881A (ja) | Ｋｖ７．２阻害剤としての新規ヘテロアリール－尿素化合物 | |
| JP2024540583A (ja) | Ｋｖ７．２エンハンサーとしてのピリジン化合物 | |
| JPWO2022120475A5 (https=) | ||
| JP6159388B2 (ja) | タンパク質凝集の阻害剤としてのフェニル−尿素及びフェニル−カルバメート誘導体 | |
| JP6542236B2 (ja) | 有機化合物 | |
| JPH1029987A (ja) | セロトニン５−ｈｔ３受容体部分活性薬 | |
| JPWO2022183288A5 (https=) | ||
| JP2009537598A (ja) | 新規１，４−ジアザ−ビシクロ［３．２．２］ノナン誘導体及びそれらの医学的使用 |